Promising findings from the first part of a clinical trial with Remygen[®]

The initial safety and dose escalation part of the Phase I/II trial ReGenerate-1 with Remygen[®] in individuals with long-term type 1 diabetes today presents preliminary results showing that the trial participants' blood sugar control improved over the nine-day treatment period. The results also support a surprising protective effect of Remygen[®] during hypoglycaemia, that is, during sharply lowered blood sugar levels. The findings in the trial are patent pending. The independent Data Safety Monitoring Board (DSMB) has previously approved the commencement of the main part of ReGenerate-1,